SEQSTER has announced the expansion of its partnership with Praxis Precision Medicines to expedite clinical trials in central nervous system (CNS) disorders.
This move aims to enhance data collection and real-world evidence (RWE) generation across the clinical development activities of Praxis, leveraging SEQSTER’s platform.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The collaboration builds upon initial work with the Essential3 Programme for Essential Tremor, extending support to the ENERGY programme focused on progressing vormatrigine as an epilepsy therapy.
SEQSTER’s platform assists in automating access to patient-consented electronic health records (EHR) throughout the US healthcare system, aiding patient screening, enrolment, and continual data gathering for the EMPOWER observational study.
EMPOWER and the related POWER clinical studies under the ENERGY programme have involved more than 5,000 patients diagnosed with epilepsy.
Praxis’s chief operating officer Megan Sniecinski said: “At Praxis, we are committed to delivering life-altering treatments to patients with CNS disorders faster and more effectively than has ever been done before.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“SEQSTER has been a foundational element of our clinical trial execution, enabling more efficient trial enrolment while capturing the longitudinal real-world data we need to advance our programmes. Our partnership represents a shared commitment to delivering better outcomes for patients and driving forward innovative ways to accelerate clinical research.”
SEQSTER CEO Ardy Arianpour said: “Praxis represents exactly the kind of innovative sponsor we built SEQSTER to support. One that understands the value of real-world data and is willing to rethink how clinical trials are conducted.
“We’re proud to have earned their trust across multiple studies and look forward to continuing this partnership as they bring transformative therapies to patients with CNS disorders.”
In July 2024, Antidote Technologies and SEQSTER partnered to improve participant identification and enrolment timelines for clinical trials.
